NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Theravance Biopharma, Inc. (TBPH) Stock Analysis

Theravance Biopharma, Inc. (TBPH) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TBPH

$17.08

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TBPH with… →

TBPH Key Statistics

As of Sep 4, 2026
Trading
Open
$17.26
Previous Close
$17.08
Day's Range
17.07–17.26
52-Week Range
13.08–21.03
Volume
160.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.24
Valuation
Market Cap
$886.77M
P/E Ratio
16.42
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.40
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.50
EPS (ttm)Profit attributable to each share over the last twelve months.
1.04
Financials (FY)
Revenue (FY)
$107.46M+66.92%
Net Income (FY)
$105.90M
Profit marginThe share of revenue left as profit after all costs and taxes.
51.58%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.92M
1-Year Return
+21.57%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
650.39K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TBPH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−8.71%
2025+98.83%
2024−16.28%
2023+0.18%
2022+1.54%
2021−37.82%
2020−31.36%
2019+1.17%
2018−8.25%
2017−12.52%
2016 (partial year)+25.31%

As of September 4, 2026.

TBPH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$107.46M$105.90M98.5%
2024$64.38M−$56.42M−87.6%
2023$57.42M−$55.19M−96.1%
2022$51.35M$872.13M1698.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$107.46M—−$3.60M$105.90M98.5%
2024$64.38M—−$42.44M−$56.42M−87.6%
2023$57.42M—−$53.29M−$55.19M−96.1%
2022$51.35M—−$79.12M$872.13M1698.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TBPH Valuation vs Biotechnology Median

Median of 656 stocks
MetricTBPHBiotechnology medianvs median
P/E16.4212.5731% above
P/S ratio8.5015.2644% below
Profit margin51.58%0.00%51.6 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Theravance Biopharma, Inc. (TBPH) is capitalised at $886.77M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 90 employees.

Over the past 52 weeks the price has ranged from $13.08 to $21.03. The most recent close on file for TBPH is $17.08, dated September 4, 2026. The close was unchanged from the previous session. The latest close sits 30.58% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $107.46M. That is +66.92% against the prior fiscal year, when revenue was $64.38M. Net income for the same year was $105.90M. The reported profit margin is 51.58%. That is 51.6 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 1.04.

Across the 4 fiscal years on file, revenue moves from $51.35M in 2022 to $107.46M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 16.42. That is 30.63% above the Biotechnology median of 12.57. On forward earnings the ratio is 13.4. The price-to-sales ratio is 8.5. On price-to-sales that is 44.3% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.25. Annualized volatility over the trailing 10 years is 49.66%. Over the trailing twelve months the price has returned +21.57%. Across 10 years the annualized return works out at −5.11%.

Growth & Income

The record shows no dividend for TBPH.

So far in 2026 the price is −8.71%. The strongest complete calendar year on file is 2025 at +98.83%; the weakest is 2021 at −37.82%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Theravance Biopharma, Inc. (TBPH) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Theravance Biopharma, Inc. TBPH $886.77M 16.4
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Theravance Biopharma, Inc. trades at a P/E of 16.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Theravance Biopharma, Inc.

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Visit website →